Incorporated in Mar.'78, P C I Chemicals and Pharmaceuticals manufactures and markets a wide range of formulations like antibiotics, antifungals, antiulcerants, protein supplements to digestive enzymes, anti-TB and anti-malarials. PCI Organics Pvt Ltd is its subsidiary.
The company's main products include Synthocilin, Syncocin, Cefacin, Clocillin, Amicasol, Cefatax, Miproten, Appetase, Konazol, Synyhopress, Insorifa, Malaquin, Rubiquin and Metasulphin. In 1994-95, it launched Myglobin syrup and Dixogyl tablet/syrup.
In Jan.'95, the company entered the capital market for the first time with equity shares at a premium of Rs 30 per share aggregating Rs 5.6 cr to finance its backward integration bulk drug project at Ankleshwar, Gujarat. The plant to be commissioned in 1996, will manufacture bulk drug intermediates, 6-APA (cap.: 10 tpa) and bulk drugs like cloxacillin sodium (cap.: 10 tpa), nalidixic acid (cap.: 40 tpa), norfloxacin (cap.: 20 tpa) and cephalexin (cap.: 10 tpa). It will retain its SSI status even after the expansion-cum-diversification.
During 1996-97, the company has launched a new product namely Roxithromycin an anti respiratory, further the structure of "Super Speciality Division" is ready and slated for lauch any time.